LI KANG BIOMEDICAL Co. Ltd. (6242) Stock Price & Analysis

6242 Stock Chart & Stats

NT$31.50-NT$0.60(-1.87%)

At close: Nov 06 12:24 AM EST

Day’s Range: TWD 31.00 - TWD 32.00
52-Week Range: TWD 31.00 - TWD 40.10
Previous Close: TWD 32.10
Volume: N/A
Average Volume (3M): 4,183
Market Cap: TWD 1.00B
Enterprise Value: TWD 1.14B
Total Cash (Recent Filing): TWD 178.22M
Total Debt (Recent Filing): TWD 160.52M
Price to Earnings (P/E): 13.1
Beta: 0.25
Next Earnings: Nov 11, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Jun 16, 2026
Dividend Yield: 6.35%

Bulls Say, Bears Say

Bulls Say

Sustained High Profitability

Persistently high gross and EBIT margins indicate that the company has maintained meaningful profitability across multiple periods. This provides an internal cushion against moderate revenue volatility and can support reinvestment, dividends, and resilience over the next several quarters.

Conservative Leverage

Low-to-moderate leverage reduces the burden of interest and refinancing obligations, preserving financial flexibility during uneven operating periods. The expansion of equity and assets further supports balance-sheet capacity for ongoing operations and measured investment.

Positive Operating Cash Flow

Positive operating cash flow shows that the core business continued to generate cash from operations, even as conversion weakened. This underlying cash contribution provides some support for liquidity and day-to-day funding, although its sustainability depends on improving conversion.

Bears Say

Negative Free Cash Flow

The sharp move to negative free cash flow is a material pressure on financial quality because operating cash no longer covered investment or working-capital requirements. If sustained, it could reduce internally funded growth capacity and increase reliance on balance-sheet resources.

Uneven Revenue And Profit Growth

A multiyear revenue decline followed by only modest 2025 growth suggests limited top-line momentum rather than a firmly established expansion trend. The accompanying reduction in net margin from about 17.6% to 14.2% also indicates that earnings growth has not matched the historical profitability profile.

Lower Returns And Rising Leverage

Although leverage remains moderate, its increase alongside a substantial decline in return on equity points to less efficient use of capital. Persistently lower returns could constrain future value creation, while higher debt adds financial obligations without evidence of a comparable improvement in profitability.

6242 FAQ

What was LI KANG BIOMEDICAL Co. Ltd.’s price range in the past 12 months?

LI KANG BIOMEDICAL Co. Ltd. lowest stock price was TWD 31.00 and its highest was TWD 40.10 in the past 12 months.

What is LI KANG BIOMEDICAL Co. Ltd.’s market cap?

LI KANG BIOMEDICAL Co. Ltd.’s market cap is TWD 1.00B.

When is LI KANG BIOMEDICAL Co. Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were LI KANG BIOMEDICAL Co. Ltd.’s earnings last quarter?

LI KANG BIOMEDICAL Co. Ltd. released its earnings results on Aug 06, 2026. The company reported TWD 0.773 earnings per share for the quarter.

Is LI KANG BIOMEDICAL Co. Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does LI KANG BIOMEDICAL Co. Ltd. pay dividends?

LI KANG BIOMEDICAL Co. Ltd. pays a ― dividend of TWD 2 which represents an annual dividend yield of 6.35%. See more information on LI KANG BIOMEDICAL Co. Ltd. dividends here

What is LI KANG BIOMEDICAL Co. Ltd.’s EPS estimate?

LI KANG BIOMEDICAL Co. Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LI KANG BIOMEDICAL Co. Ltd. have?

LI KANG BIOMEDICAL Co. Ltd. has 31,806,500 shares outstanding.

What happened to LI KANG BIOMEDICAL Co. Ltd.’s price movement after its last earnings report?

LI KANG BIOMEDICAL Co. Ltd. reported an EPS of TWD 0.773 in its last earnings report. Following the earnings report the stock price went down -1.143%.

Which hedge fund is a major shareholder of LI KANG BIOMEDICAL Co. Ltd.?

Currently, no hedge funds are holding shares in TW:6242

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description